



April–June in brief

- **Net sales** rose by about 48 percent to SEK 8,578k (5,812k).
- **Operating result before depreciation and amortization (EBITDA)*** totaled SEK -596k (-1,624).
- **Comprehensive income for the period** improved by SEK 352k to a loss of SEK 1,793 (loss: 2,145k).
- **Comprehensive income per share**, basic and diluted, improved by SEK 0.01 to SEK -0.03 (-0.04).
- **Genovis signed distribution agreement for the South Korean market**
- **Strengthened marketing organization in the US and Kevin Cook hired as Senior Application & Market Area Manager for the subsidiary Genovis Inc.**
- **Expanded product portfolio and launched GlycOCATCH™, the first product in the company's new protein purification product category.**
- **Carried out a directed share issue that raised SEK 10.1 million for the company before transaction costs.**

* Genovis has chosen to apply IFRS 16 in advance, as well as the simplification rule regarding short-term leases. Consequently, this will not have any effect on the figures reported for 2017. Costs for rent and leases are therefore recognized under depreciation and amortization and beginning in 2018 will not affect EBITDA for the Group. Read more under accounting policies, page 10.

Events after the end of the period

Genovis expanded its sales and marketing organization at its Lund headquarters and hired Rob Horsefield as Sales & Business Development Manager. Rob has several years of experience in the industry from sales in analytical chemistry, pharmaceutical development and protein chemistry.

Financial summary	2018	2017	2018	2017	2017
(SEK 000s)	April – June	April – June	Jan. – June	Jan. – June	full-year
Net sales	8,578	5,812	14,825	10,607	22,867
Gross profit/loss	7,696	5,887	14,062	10,017	21,841
Gross margin* (%)	90	86	90	87	90
Operating profit/loss	(1,925)	(1,978)	(3,292)	(5,037)	(7,835)
Comprehensive income for the period	(1,793)	(2,145)	(3,189)	(5,215)	(8,112)
Comprehensive income per share based on a weighted average of the number of outstanding shares	(0.03)	(0.04)	(0.05)	(0.09)	(0.17)
Cash flow from operating activities	80	(3,662)	(1,944)	(5,445)	(8,355)
Cash and cash equivalents at close of period	10,293	8,194	10,293	8,194	4,918

*Excluding other revenue and inventory finished goods.

Half year in brief

- **Net sales** rose by about 40 percent to SEK 14,825k (10,607k).
- **Gross profit** improved by SEK 4,045k and totaled SEK 14,062k (10,017k).
- **Operating result** improved by SEK 1,745k and totaled -3,292k (-5,037k).
- **Comprehensive income for the period** improved by SEK 2,026 to a loss of SEK 3,189 (loss: 5,215k).
- **Comprehensive income per share**, basic and diluted, improved by SEK 0.04 to SEK -0.05 (-0.09).

Comments from Fredrik Olsson, Chief Executive Officer



Extremely strong sales growth in Q2

The extremely strong growth at the beginning of the year continued during the second quarter: sales surged 48 percent compared with the previous year and totaled SEK 8.6 million (5.8). This is the single best sales quarter in the history of Genovis. Thus we have now had 15 quarters with sales growth (YoY). For the half year, sales totaled approximately SEK 14.8 million, which represents sales growth of about 40 percent for the first six months of the year. The strong sales with a continued high gross margin creates a good platform for long-term sustainable growth and profitability.

Our sales grew on all markets during the quarter. Our strategy is still to have a presence in all key markets and right now Asia is our priority, with the goal of signing contracts during the year for Japan, Singapore and Taiwan. The increase in sales is driven by increased demand, both for our more mature products that have been on the market for a few years and because our recently launched products have rapidly been accepted on the market. This is a clear confirmation that our strategy and business model with customer-focused innovation creates value and growth opportunities for Genovis. In particular, our product portfolio in the glycomics area has achieved faster sales growth. We realized there was a pronounced need in the market for new analytical tools in the field of glycomics, but the response has been both larger and faster than we had initially expected. During the quarter we expanded our portfolio with yet another product in glycomics, GlycOCATCH™, which is our first product for protein purification. Two important scientific articles from the US Food and Drug Administration (FDA) and Johns Hopkins University School of Medicine were published during the summer. Both of these articles demonstrate new and different applications for our glycomics portfolio, which in the long term will open completely new business opportunities for Genovis.

Genovis is in a growth phase and against this background we carried out a rights issue during the quarter with the goal of continuing to strengthen and grow our sales and marketing organization. In addition to the previously announced recruitment of Kevin Cook to our US organization, Rob Horsefield is now joining the Genovis team in Lund. Rob Horsefield brings valuable industry experience and will initially promote our expansion in the Asian markets and develop our business in relation to partners and potential wholesalers, as well as support our continued growth in Europe.

With more than half of 2018 behind us, the beginning of the third quarter clearly indicates continued sales growth. The investments that we have made during the quarter to strengthen our marketing organization and to secure the right patent protection are crucial for us to be able to maintain the high pace of our development portfolio and sales moving forward.

I confidently look forward, along with our expanding team, to accompanying Genovis on its continued journey of growth.

Genovis Group in brief




Genovis' enzymes are in a market that covers the entire life science and biotech supply industry. The Parent Company in Lund handles sales in the European market and the subsidiary, Genovis Inc., handles all sales in the North American market. In Asia Genovis works both with direct sales and with distributors who are familiar with the local market.

Genovis' business model has a long-term and sustainable focus based on two primary strategies that together are the drivers of the Company's success:

- continuing to launch unique new products, thereby growing the product portfolio, and
- deliberately working to encourage customers to use Genovis products in several stages farther along on the drug development value chain.

The Company will therefore continue to be creative and develop unique new high-value products for its customers. New products are mainly aimed at customers who work in the discovery phase or in preclinical development. In this phase most of the Company's customers are both curious and willing to test new analytical methods to address the clear needs and challenges related to analyzing biological drugs. Genovis rapidly achieved sales of the newly launched products, which is a clear stamp of quality demonstrating that the Company contributes innovation to the drug development process. Genovis also works on introducing existing products to customers in other parts of the value chain, especially in production and quality control for clinical use.



Performance

The Group's financial performance in summary

(SEK 000s)	2018 April – June	2017 April – June	2018 Jan. – June	2017 Jan. – June	2017 full-year
Net sales	8,578	5,812	14,825	10,607	22,867
Change in inventory, finished goods	(177)	911	509	767	1,317
Other operating income*	155	0	213	0	23
Raw materials and consumables	(860)	(836)	(1,485)	(1,357)	(2,366)
Gross profit/loss	7,696	5,887	14,062	10,017	21,841
<i>Gross profit/loss excluding other operating income</i>	<i>7,541</i>	<i>5,887</i>	<i>13,849</i>	<i>10,017</i>	<i>21,818</i>
Gross margin** (%)	90	86	90	87	90


*Relates to exchange rate gains

**Excl. other revenue and "Change in inventory, finished goods."

Net sales

Consolidated net sales for the period rose to SEK 14,825k (10,607k), an increase in sales of about 40 percent. Net sales for the second quarter amounted to SEK 8,578k (5,812k), corresponding to about a 48 percent increase in sales.

Sales by quarter 2015–2018



Operating profit/loss before depreciation and amortization (EBITDA)

Operating result before depreciation and amortization for the period totaled SEK -611k (-4,353k). Operating result before depreciation and amortization for the second quarter totaled SEK -596k (-1,624k). Genovis has chosen to apply IFRS 16 in advance. As a result of the transition to IFRS 16, the Company's other external expenses will decrease, while depreciation, amortization, financial expenses and the balance sheet will increase. The Group is applying IFRS 16 retroactively as well as the simplification rule regarding short-term leases. Consequently, this will not require any restatement for January – June 2017. Read more under accounting policies, page 10.

Operating profit/loss (EBIT)

EBIT for the period was a loss of SEK 3,292k (loss: 5,037k), corresponding to an improvement of SEK 1,745k. Operating loss after depreciation, amortization and impairment for the second quarter was SEK 1,925k (loss: 1,978k), corresponding to an improvement of SEK 53k.

Comprehensive income

Comprehensive income for the period improved by SEK 2,026k to a loss of 3,189k (loss: 5,215k). Earnings per share, based on a weighted average of the number of outstanding shares, improved by 0.04 to SEK -0.05 (-0.09). Comprehensive income for the second quarter improved by SEK 352k to a loss of SEK 1,793k (loss: 2,145k). Earnings per share, based on a weighted average of the number of outstanding shares, improved by 0.01 to SEK -0.03 (-0.04)

Costs

Consolidated expenses for the period increased by SEK 2,428k to SEK 18,839k (16,411k). Expenses are allocated as follows: raw materials and consumables, which increased by SEK 128k to SEK 1,485 (1,357k), personnel costs, which increased by SEK 1,458k to SEK 8,059k (6,601k), other external expenses, which decreased by SEK 947k to SEK 6,614k (7,561k) and other operating expenses, which decreased by SEK 208k to 0 (208k). Personnel costs increased because of the new employees hired to strengthen sales and marketing worldwide, and also because Directors' remuneration for 2018 was paid as salary and recognized under personnel costs. In addition, some items causing the increase were non-recurring. The transition to IFRS 16 resulted in a decrease in other external expenses, depreciation and amortization, as well as an increase in financial expenses. Depreciation and amortization for the period increased by SEK 1,997k to SEK 2,681k (684k). Expenses for the second quarter increased by SEK 1,780k to SEK 10,481k (8,701k). Expenses are allocated as follows: raw materials and consumables SEK 860k (836k), personnel costs SEK 4,590k (3,453k) other external expenses SEK 3,702k (3,980k) and other operating expenses 0 (78k). Depreciation and amortization for the second quarter totaled SEK 1,329k (354k).

Investments

Consolidated capital expenditure for the period totaled SEK 924k (1,397k), of which SEK 629k (431k) is attributable to property, plant, and equipment, primarily laboratory equipment and computers, and SEK 295k (966k) is attributable to investments in intangible assets. For the second quarter net capital expenditure amounts to SEK 328k (704k), including SEK 63k (0) attributable to investments in property, plant, and equipment and SEK 265k (704k) attributable to investments in intangible assets.

Cash flow and financial position

Total shareholders' equity for the Group was SEK 24,494k (21,085k) after taking the result for the period into account. Equity per share based on the weighted average of the number of outstanding shares (basic and diluted) at the end of the period was SEK 0.40 (0.37). The Group's equity ratio at the end of the period was 57 (80) percent.

Consolidated cash and cash equivalents at the end of the period amounted to SEK 10,293k (8,194k). Taking into account the private placement in April 2018, which raised about SEK 10.1 million for the Company before issue expenses, along with expected revenue, the Board believes that the existing working capital is sufficient to run the Company over the next twelve months.

Consolidated cash flow for the period was SEK 5,375k (3,913k). Cash flow from financing activities totaled SEK 8,243k (10,755k). Consolidated cash flow for second quarter was SEK 8,621k (6,389k) and cash flow from financing activities totaled SEK 8,869k (10,755k).

Only the Group has interest-bearing liabilities, where liabilities to credit institutions relate in their entirety to the present value of estimated future lease payments, which also includes rent for premises.

Liabilities to credit institutions

Noncurrent interest-bearing liabilities	
<i>Maturity between 1 and 4 years</i>	9,694,327
Current interest-bearing liabilities	
<i>Maturity within 1 year</i>	1,251,786

Taxes

The Group has a deferred tax asset that arises from the Parent Company, amounting to SEK 1,718k (1,718k) at the end of the period.

Employees

On June 30, 2018, the Group had nineteen employees, compared with the same period the previous year, when the Group had seventeen employees. Eighteen people are employed by the parent company in Lund and one person works for the subsidiary Genovis Inc. in the US.

Share capital and share performance

Share capital at the end of the period amounted to SEK 15,775,000 and the total number of shares amounted to 63,100,000 with a par value of SEK 0.25. Genovis' shares are traded on Nasdaq First North Stockholm under the ticker symbol GENO. First North is Nasdaq's European emerging market intended for small, growing businesses, with a less extensive rulebook than the main market. Erik Penser Bank is the Certified Advisor for Genovis; T: +46 (0)8-463 83 00.

Parent Company

Net sales and operating profit/loss in the Parent Company are attributable to the primary and only business area: product sales and/or outlicensing of research-based innovations. According to Genovis, the Company does not meet the definition of geographical areas under IAS 14 and therefore no secondary segment information is provided.

Revenue

Revenue for the period, including change in inventory finished goods, amounted to SEK 12,975k (9,076k) including SEK 12,253k (9,076k) attributable to revenue from sales and SEK 213k (0) to other revenue. Revenue for the second quarter was SEK 7,203k (5,374k), including SEK 7,048k (5,374k) attributable to revenue from sales and SEK 155k (0) to other revenue.

Costs

Operating expenses for the period totaled SEK 16,161k (14,341k) and expenses for the second quarter totaled SEK 8,763k (7,758k).

Performance

Net loss was SEK 3,187k (loss: 5,265k) for the period and SEK 1,561k (loss: 2,384k) for the second quarter.

Investments

Capital expenditure for the period totaled SEK 924k (1,397k), of which SEK 629k (431k) is attributable to property, plant, and equipment, primarily laboratory equipment and computers, and SEK 295k (966k) is attributable to investments in intangible assets. For the second quarter net capital expenditure amounts to SEK 328k (704k), including SEK 63k (0) attributable to investments in property, plant, and equipment and SEK 265k (704k) attributable to investments in intangible assets.

Taxes

The Parent Company has a deferred tax asset amounting to SEK 1,718k (1,718k) at the end of the period, corresponding to a loss carryforward of SEK 7,809k. The loss-carryforward is expected to be utilized in the foreseeable future. The Company's total tax loss amounts to SEK 161k (119k).

Subsidiary Genovis Inc.

The subsidiary Genovis Inc. handles all sales in the North American market.

Related party transactions

Genovis' board member and principal owner Mikael Lönn, who holds a 20.72 percent stake in Genovis, owns 12.24 percent of the shares in Redeye AB, for which Mikael Lönn is also a board member. Genovis has purchased analysis services during the period from Redeye AB for a total of SEK 816k. Chairman of the board Mårten Winge has provided consultancy services during the six-month period for a total of SEK 40k.

Outlook

Although the Life Science field is relatively independent of business cycles, periods of uncertainty can influence our customers' appetite to invest in new technology. With all development projects proceeding according to plan, Genovis is positioned to make additional advances with respect to both new products and sales. Taken together, volume growth is expected to be positive in 2018.

Risk Factors

Genovis' general view of the financial risks that could affect operations has not changed since the description published in the most recent annual report. Genovis' business risks include the risk that anticipated revenue might not materialize since the Company is active in a market in which competing companies have substantially larger financial resources at their disposal. For a detailed overview of the Company's financial risks please refer to page 54 in Genovis' 2017 annual report.

Future reporting dates

Interim Report	January 1 – September 30	November 27, 2018
Year-end Report	January 1 – December 31	February 26, 2019

Interim reports may be ordered from the Company or downloaded at the Genovis website:

www.genovis.com.

Genovis AB, Box 790

SE-220 07 Lund, Sweden

T: +46 (0)46-10 12 30, Fax: +46 (0)46-12 80 20

Accounting policies

This interim report for the Group has been prepared in accordance with IAS 34 Interim Financial Reporting and the relevant provisions of the Swedish Annual Accounts Act. The report for the Parent Company has been prepared in accordance with chapter 9 of the Swedish Annual Accounts Act, Interim Reports. The accounting policies applied for the Group and the Parent Company are consistent with the accounting policies used in the preparation of the most recent annual report.

IFRS 15 – Revenue recognition

IFRS 15 governs the recognition of revenue. The principles on which IFRS 15 is based will provide users of financial statements with more useful information about the company's revenue. Under this increased disclosure requirement, information must be provided on the revenue's nature, timing and uncertainty in connection with revenue recognition, as well as cash flows arising from customers with contracts. According to IFRS 15 revenue should be recognized when the customer assumes control of the sold goods or service and is able to use or benefit from the goods or service. IFRS 15 replaces IAS 18 Revenue and IAS 11 Construction Contracts as well as the related SIC and IFRIC interpretations. IFRS 15 entered into force on January 1, 2018. Implementation of IFRS 15 will not materially affect how the Group reports revenue and consequently, there is no need for a transition method.

IFRS 16 Financial Instruments

Genovis has chosen to apply IFRS 16 commencing on January 1, 2018. IFRS 16 replaces the IFRS standards that currently regulate accounting for leasing – specifically IAS 17, IFRIC 4, SIC-15 and SIC-27. The challenge of IFRS 16 is that a much greater variety of contracts are now covered by these judgements and estimates, including leases that are capitalized as assets and liabilities in the balance sheet, with the effect that the cost in the income statement is allocated to depreciation of operating income and interest expense in net financial items. The Company is applying the simplified approach for the transition. The standard requires assets and liabilities arising from all leases, with some exceptions, to be recognized in the balance sheet. This model reflects that, at the start of a lease, the lessee obtains the right to use an asset for a period of time and has an obligation to pay for that right. In the income statement, depreciation is reported separately from interest expense attributable to the lease liability. Implementation of IFRS 16 has affected the Group's balance sheet in that total noncurrent assets increased by SEK 9,320, liabilities to credit institutions are higher by SEK 9,254k (current liabilities by SEK 1,878k and noncurrent liabilities by SEK 7,376k). In the income statement, a transfer was made from raw materials and consumables (SEK 118k) and other external expenses (567k) to depreciation and amortization (SEK 633k) and financial expenses (SEK 52k). As a result, EBITDA has increased from a loss of SEK 701, to a loss of SEK 16k. The Group is applying IFRS 16 retroactively as well as the simplification rule regarding short-term leases. Consequently, this will not require any restatement of 2017.

Consolidated statement of comprehensive income

(SEK 000s)	2018 April-June	2017 April-June	2018 Jan.- June	2017 Jan.-June	2017 full-year
Net sales	8,578	5,812	14,825	10,607	22,867
Change in inventory, finished goods	(177)	911	509	767	1,317
Other operating income	155	0	213	0	23
Raw materials and consumables	(860)	(836)	(1,485)	(1,357)	(2,366)
Gross profit/loss	7,696	5,887	14,062	10,017	21,841
Personnel costs	(4,610)	(3,453)	(8,059)	(6,601)	(13,230)
Other external expenses	(3,681)	(3,980)	(6,614)	(7,561)	(14,630)
Other operating expenses	0	(78)	0	(208)	(207)
Operating profit/loss before depreciation and amortization (EBITDA)	(596)	(1,624)	-611	(4,353)	(6,226)
Depreciation, amortization and impairment of plant, property, and equipment and intangible assets	(1,329)	(354)	(2,681)	(684)	(1,609)
Operating profit/loss (EBIT)	(1,925)	(1,978)	(3,292)	(5,037)	(7,834)
Net financial items	(47)	(14)	(100)	(15)	(91)
Profit/loss after financial items	(1,972)	(1,992)	(3,392)	(5,052)	(7,926)
Taxes	50	(45)	(0)	(52)	(22)
Profit/loss after tax for the period	(1,922)	(2,037)	(3,392)	(5,104)	(7,948)
Items that may be reclassified subsequently to profit or loss					
Translation of foreign subsidiary	129	(108)	203	(111)	(164)
Comprehensive income for the period	(1,793)	(2,145)	(3,189)	(5,215)	(8,112)
-attributable to shareholders in Genovis AB	(1,793)	(2,145)	(3,189)	(5,215)	(8,112)

	2018 April-June	2017 April-June	2018 Jan.-June	2017 Jan.-June	2017 full-year
Earnings per share (SEK)*					
Based on weighted average of the number of outstanding shares (basic and diluted)*.	(0.03)	(0.04)	(0.05)	(0.09)	(0.14)
Number of outstanding shares	63,100,000	60,294,162	63,100,000	60,294,162	60,294,162
Weighted average for the period	61,239,950	58,889,668	60,764,414	57,081,871	58,692,491
Number of shares at beginning of period	60,294,162	55,294,162	60,294,162	55,294,162	55,294,162
Number of shares at end of period	63,100,000	60,294,162	63,100,000	60,294,162	60,294,162
Share price at end of period, SEK	3.80	3.05	3.80	3.05	3.24

Condensed consolidated balance sheet

(SEK 000s)	2018	2017	2017
Assets	June 30	June 30	Dec. 31
<i>Noncurrent assets</i>			
Intangible assets	3,183	4,046	4,042
Property, plant and equipment	12,215	1,189	3,022
Financial assets	1,718	1,718	1,718
Current assets	15,310	11,200	12,606
Cash and cash equivalents	10,293	8,194	4,918
Total assets	42,719	26,347	26,306

Equity and liabilities

Equity	24,494	21,085	18,188
Noncurrent liabilities	9,694	0	2,067
Current liabilities	8,531	5,262	6,051
Total equity and liabilities	42,719	26,347	26,306

Consolidated statement of changes in equity

(SEK 000s)	2018	2017	2017
	Jan.-June	Jan.-June	Jan.-Dec.
Amount at start of period	18,188	15,545	15,545
Rights issue	9,495	10,755	10,755
Exchange rate difference	203	(111)	(164)
Net loss for the period	(3,392)	(5,104)	(7,948)
Amount at end of period	24,494	21,085	18,188
Attributable to shareholders in Genovis AB	24,494	21,085	18,188

	2018	2017	2017
Key financial figures	June 30	June 30	Dec. 31
Equity/assets ratio (%)	57	80	69
Equity per share at end of period* (SEK)	0.40	0.37	0.31

* Based on weighted average of the number of outstanding shares (basic and diluted).

Summary Consolidated Cash Flow Statement

(SEK 000s)	2018	2017	2018	2017	2017
	April-June	April-June	Jan.-June	Jan.-June	full-year
Cash flow from operations	(1,300)	(1,977)	(2,042)	(5,037)	(7,938)
Adjustment for items not affecting cash flow	697	354	1,416	684	1,281
Change in working capital	730	(2,025)	(1,218)	(1,077)	(1,698)
Net financial items	(47)	(14)	(100)	(15)	0
Cash flow from operating activities	80	(3,662)	(1,944)	(5,445)	(8,355)
Investing activities	(328)	(704)	(924)	(1,397)	(1,763)
Cash flow after investing activities	(248)	(4,366)	(2,868)	(6,842)	(10,118)
Financing activities	-626	0	(1,252)	0	0
Rights issue	9,495	10,755	9,495	10,755	10,755
Cash flow for the period	8,621	6,389	5,375	3,913	637
Cash and cash equivalents at start of period	1,672	1,805	4,918	4,281	4,281
Cash and cash equivalents at close of period	10,293	8,194	10,293	8,194	4,918

Parent Company

Summary Income Statement

(SEK 000s)	2018 April- June	2017 April- June	2018 Jan.-June	2017 Jan.-June	2017 full-year
Operating income incl. change in inventory, finished goods	7,203	5,374	12,975	9,076	19,499
Operating expenses	(8,763)	(7,758)	(16,161)	(14,341)	(27,739)
Operating profit/loss	(1,560)	(2,384)	(3,186)	(5,265)	(8,240)
Net financial items	(1)	0	(1)	0	0
Net loss for the period	(1,561)	(2,384)	(3,187)	(5,265)	(8,240)

Summary Balance Sheet

(SEK 000s)	2018 June 30	2017 June 30	2017 Dec. 31
Assets			
Noncurrent assets	6,210	6,968	6,702
Current assets	15,236	12,416	12,243
Cash and cash equivalents	8,067	5,931	4,032
Total assets	29,513	25,315	22,977

Equity and liabilities

(SEK 000s)	2018 June 30	2017 June 30	2017 full-year
Equity			
Restricted equity	15,775	15,074	15,074
Unrestricted equity	8,225	5,593	2,618
Liabilities			
Current liabilities	5,513	4,648	5,285
Total equity and liabilities	29,513	25,315	22,977

Statement of changes in equity

(SEK 000s)	2018 Jan.-June	2017 Jan.-June	2017 full-year
Amount at start of period	17,692	15,177	15,177
Rights issue	9,495	10,755	10,755
Net loss for the period	(3,187)	(5,265)	(8,240)
Amount at end of period	24,000	20,667	17,692
Attributable to shareholders in Genovis AB	24,000	20,667	17,692

Summary Statement of Cash Flows (SEK 000s)	2018 April-June	2017 April-June	2018 Jan.-June	2017 Jan.-June	2017 full-year
Cash flow from operations	(1,602)	(2,187)	(3,185)	(5,264)	(8,240)
Adjustment for items not affecting cash flow	697	337	1,416	649	1,281
Change in working capital	(1,032)	(2,723)	(2,766)	(865)	(53)
Net financial items	(1)	0	(1)	0	0
Cash flow from operating activities	(1,938)	(4,573)	(4,536)	(5,480)	(7,012)
Investing activities	(328)	(704)	(924)	(1,397)	(1,764)
Cash flow after investing activities	(2,266)	(5,277)	(5,460)	(6,877)	(8,776)
Financing activities	9,495	10,755	9,495	10,755	10,755
Cash flow for the period	7,229	5,478	4,035	3,878	1,979
Cash and cash equivalents at start of period	838	453	4,032	2,053	2,053
Cash and cash equivalents at close of period	8,067	5,931	8,067	5931	4,032

Statement

The Board of Directors and the Chief Executive Officer certify that this interim report provides a true and fair overview of the development of the Parent Company's and the Group's business activities, financial position and results of operations as well as the significant risks and uncertainties to which the Parent Company and the companies included in the Group are exposed.

This report has not been subject to special review by the Company's auditors.

Lund August 28, 2018

Genovis AB (publ.)

On behalf of the Board of Directors Fredrik Olsson
President & CEO

For more information, please contact:

Fredrik Olsson, CEO

T: +46 (0)46-10 12 33

This information is information that Genovis AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person set out above, on August 28, 2018.

This information is also available in Swedish.